{"id":"W4281666355","doi":"10.1200/jco.22.01003","title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke","funders":"National Cancer Institute; Genentech; Eisai; National Institute for Health and Care Research; MacroGenics; Clovis Oncology; NuCana; Novocure; Puma Biotechnology; Regeneron Pharmaceuticals; Array BioPharma; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Amgen; Pfizer","keywords":"Medicine; Population; Hazard ratio; Internal medicine; Ovarian cancer; Clinical endpoint; Placebo; Oncology; BRCA mutation; Surgery; Cancer; Clinical trial; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006626099,0.0003539748,0.003734326,0.0003637922,0.0001200431,0.000017756,0.0003000996,0.0002324909,0.002344241],"category_scores_gemma":[0.001610801,0.0002319712,0.0008287961,0.0004455168,0.000246237,0.0001278383,0.00005041501,0.001167525,0.00001700017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002277472,"about_ca_system_score_gemma":0.0050729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000775651,"about_ca_topic_score_gemma":0.0002051313,"domain_scores_codex":[0.991651,0.002605872,0.0037346,0.0004844511,0.001004908,0.0005191932],"domain_scores_gemma":[0.992348,0.003370813,0.002686708,0.0004091932,0.000523543,0.0006617922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8868774,0.01075961,0.004140001,0.000004653581,0.001083628,0.0005454744,0.001228782,0.001135322,0.00002710477,0.00009323227,0.003099129,0.09100565],"study_design_scores_gemma":[0.8412972,0.07603286,0.002679373,0.0001130988,0.0004875579,0.00004606901,0.0001462507,0.0002081003,0.00003457932,0.0004500529,0.07829754,0.0002073327],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9725434,0.0004131105,0.0006040084,0.01882882,0.002665017,0.004083162,0.00004043208,0.00001880558,0.0008032287],"genre_scores_gemma":[0.9750015,0.001616196,0.002181466,0.01681982,0.001918686,0.001688972,0.00001449405,0.00007036678,0.0006885434],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09079832,"threshold_uncertainty_score":0.9985678,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1037382995368031,"score_gpt":0.4865092343933121,"score_spread":0.382770934856509,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}